They are absolutely frightened by the prospect of a competitor coming in with a cheaper, more consistent and more potent product. Which is exactly what Cynata offers. If I held MSB and objectively read the announcement today, I would be petrified and running for the hills. That announcement conveys a management team that knows they are living on borrowed time.
What they specifically included and excluded from that announcement painted a clear picture of where they see the threat to their business model. That threat is Cynata.
Why Orphan Drug Designation for mesoblast is IRRELEVANT to Cynata, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.5¢ | 16.0¢ | $10.82K | 65.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4450 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 88474 | 2 |
View Market Depth
| Last trade - 15.32pm 20/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |